Muscle wasting: emerging pathways and potential drug targets.

Abstract

Muscle wasting is a serious comorbidity associated with many disorders, including cancer, kidney disease, heart failure, and aging. Progressive loss of skeletal muscle mass negatively influences prognosis and survival, and is often accompanied by frailty and poor quality of life. Clinical trials testing therapeutics against muscle wasting have yielded limited success. Some therapies improved muscle mass in patients without appreciable differences in physical performance. This review article discusses emerging pathways that regulate muscle atrophy, including oncostatin M (OSM) and ectodysplasin A2 (EDA2) receptor (EDA2R) signaling, outcomes of recent clinical trials, and potential drug targets for future therapies.

• Authors: Aylin Domaniku, Sevval Nur Bilgic, Serkan Kir
• Journal: Trends in pharmacological sciences (Trends Pharmacol Sci) Vol. 44 Issue 10 Pg. 705-718 (10 2023) ISSN: 1873-3735 [Electronic] England
• PMID: 37596181 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2023 Elsevier Ltd. All rights reserved.

Topics

• Humans
• Quality of Life
• Muscular Atrophy (drug therapy)
• Aging
• Drug Delivery Systems
• Muscles